Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Dificid (fidaxomicin by Year
Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M)
Merck Dificid (fidaxomicin: $247M in FY2025, down 27.4% from a year earlier.
Where the FY2025 figure comes from
“|| Dificid | 34 | 22 | 56 | 83 | 96 | 179 | 43 | 25 | 247 | -77 | -77 | -69 | -69”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dificid (fidaxomicin — C. difficile infection) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 247 | -27.4% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 340 | +12.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 302 | +14.8% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 263 | +50.3% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 175 | +59.1% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 110 | – | Form 10-K (filed 2023-02-24) ↗ |
Breakdown
What makes up dificid (fidaxomicin
- Dificid (fidaxomicin — C. difficile infection) — U.S. sales ($M)202 · FY2025
- Dificid (fidaxomicin — C. difficile infection) — International sales ($M)45 · FY2025
- Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%)-27.0% · FY2025
- Dificid (fidaxomicin — C. difficile infection) — Worldwide constant-currency (ex-exchange) growth YoY (%)-27.0% · FY2025
Cite this data
StockData. (2026). Merck Dificid (fidaxomicin ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dificid
See every metric in the Merck KPI table. Data updated Oct 26, 2026.